Arrowhead Pharmaceuticals Inc. (ARWR)

5.54
NASDAQ : Health Technology
Prev Close 5.54
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.42 / 6.75
Avg Volume 1.73M
Exchange NASDAQ
Shares Outstanding 86.79M
Market Cap 483.41M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV For Treatment Of Hepatitis B

Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV For Treatment Of Hepatitis B

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a...

Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results

Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 first quarter ended December 31, 2017.

Arrowhead Pharmaceuticals To Webcast Fiscal 2018 First Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2018 First Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Friday, February 9, 2018, at 4:30 p.

Arrowhead Pharmaceuticals Closes Underwritten Public Offering With Gross Proceeds Of $60.4 Million

Arrowhead Pharmaceuticals Closes Underwritten Public Offering With Gross Proceeds Of $60.4 Million

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 22, 2018 it closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued...

Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering Of Common Stock

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering Of Common Stock

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.

Arrowhead Pharmaceuticals Appoints William Waddill To Board Of Directors

Arrowhead Pharmaceuticals Appoints William Waddill To Board Of Directors

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors elected veteran biotechnology executive William Waddill as an independent director of the company, with a term beginning effective...

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it filed a regulatory submission to begin a Phase 1/2 study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic...

Arrowhead Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $3.25, changing hands for $3.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it filed a regulatory submission to begin a first-in-human study of ARO-AAT, a second-generation investigational medicine for the treatment of alpha-1 liver...

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(C)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(C)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 11, 2017, five new employees were awarded "inducement" grants under Rule...

Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results

Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 fourth quarter and year ended September 30, 2017.

Fed, Oil, Comcast and Boeing - 5 Things You Must Know Before the Market Opens

Fed, Oil, Comcast and Boeing - 5 Things You Must Know Before the Market Opens

U.S. stock futures point to a mixed start for Wall Street on Tuesday, as the Federal Reserve gets ready to kick off its two-day policy meeting in Washington.

Arrowhead Presents New Clinical Data Demonstrating A Sustained Host Response In Hepatitis B Patients Following RNAi Therapy

Arrowhead Presents New Clinical Data Demonstrating A Sustained Host Response In Hepatitis B Patients Following RNAi Therapy

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presented new data from the company's Phase 2 clinical study in patients that received multiple doses of ARC-520, the company's prior generation RNAi-based clinical candidate...

Arrowhead Pharmaceuticals To Webcast 2017 Fiscal Year End Results

Arrowhead Pharmaceuticals To Webcast 2017 Fiscal Year End Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, December 12, 2017, at 4:30 p.

First Week of ARWR June 2018 Options Trading

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 196 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Present At 29th Annual Piper Jaffray Healthcare Conference

Arrowhead To Present At 29th Annual Piper Jaffray Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: 29th Annual Piper Jaffray Healthcare Conference - New York, November 28-29,...

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 17, 2017, eight new employees were awarded "inducement" grants of options under...

Arrowhead Presents Promising Preclinical Data On Development Of ARO-AAT For Treatment Of Alpha-1 Liver Disease At Liver Meeting® 2017

Arrowhead Presents Promising Preclinical Data On Development Of ARO-AAT For Treatment Of Alpha-1 Liver Disease At Liver Meeting® 2017

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented data from studies demonstrating promising preclinical safety and efficacy of ARO-AAT, a second-generation investigational medicine for the treatment of alpha-1...

Arrowhead Pharmaceuticals To Present Preclinical Data On ARO-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals To Present Preclinical Data On ARO-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for the treatment of alpha-1 liver disease that uses Arrowhead's...

Arrowhead To Present At Chardan Gene Therapy Conference

Arrowhead To Present At Chardan Gene Therapy Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Chardan Gene Therapy Conference - New York, October 10, 2017 October...

Arrowhead Data Reveal Important Considerations For Future Hepatitis B Treatment

Arrowhead Data Reveal Important Considerations For Future Hepatitis B Treatment

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced results from studies of ARC-520, a prior-generation RNAi therapeutic candidate against chronic hepatitis B virus (HBV) infection, in a Phase 2 clinical study in...

Arrowhead Hosts Investor & Analyst R&D Day To Introduce TRiM™ Platform And Lead RNAi-based Drug Candidates

Arrowhead Hosts Investor & Analyst R&D Day To Introduce TRiM™ Platform And Lead RNAi-based Drug Candidates

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), is hosting an investor & analyst R&D day in New York today to introduce its proprietary Targeted RNAi Molecule (TRiM TM) platform and review its pipeline of RNAi...

Arrowhead To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

Arrowhead To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming event: 2017 Cantor Fitzgerald Global Healthcare Conference - New York, September...

Arrowhead Pharmaceuticals To Host R&D Day On RNAi-Based Therapies

Arrowhead Pharmaceuticals To Host R&D Day On RNAi-Based Therapies

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development Day to discuss its pipeline of RNAi-based therapies on September 14 in New York City.

Arrowhead Reports Fiscal 2017 Third Quarter Results

Arrowhead Reports Fiscal 2017 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 third quarter ended June 30, 2017.

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Thursday, August 3, 2017, at 4:30 p.

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 5, 2017, eleven new employees were awarded "inducement" grants of options under Rule...

TheStreet Quant Rating: D- (Sell)